Hepatitis C: all 2,356 studies
Page 21 of 24. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.
- Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis CCompletedNCT00778843Phase 3
- VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.CompletedNCT00775125Phase 1
- sgp130 in Chronic Human Liver DiseaseCompletedNCT00770198
- A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333CompletedNCT00768690Phase 1
- Genetic Analysis of Liver CancerTerminatedNCT00768001
- Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular CarcinomaTerminatedNCT00767936
- 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis CCompletedNCT00763568Phase 2
- Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C PatientsCompletedNCT00759200Phase 2
- Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral HepatitisTerminatedNCT00755950Phase 2/3
- Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis CCompletedNCT00755742Not applicable
- A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected AdultsCompletedNCT00752687Phase 1
- TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend CapsuleCompletedNCT00752648Phase 1
- Treatment of Hepatitis C in Psychiatric PatientsCompletedNCT00751426
- Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical TherapyCompletedNCT00749138Phase 1
- Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV TherapyCompletedNCT00747539
- Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV InfectionCompletedNCT00743795Phase 2
- TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.CompletedNCT00741169Phase 1
- Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)CompletedNCT00730431Phase 1
- Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)TerminatedNCT00727077
- Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCVCompletedNCT00725803Phase 2
- Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C PatientsCompletedNCT00724776Phase 1
- PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)CompletedNCT00724620Phase 4
- Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)CompletedNCT00724295
- Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)CompletedNCT00724230
- Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)TerminatedNCT00723879
- The Role of Dendritic Cells in Hepatitis C InfectionCompletedNCT00723242Not applicable
- A Multiple Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00722358Phase 2
- Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis CCompletedNCT00718172Phase 1
- Assessment of Biomarkers for Recurrent HCV Infection Post-liver TransplantationCompletedNCT00710801
- Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus InfectionCompletedNCT00707850Phase 4
- Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus InfectionCompletedNCT00707772Phase 4
- Chronic Hepatitis C and Insulin ResistanceCompletedNCT00707603
- An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)WithdrawnNCT00704756
- HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C PatientsStatus unknownNCT00703872Phase 2
- Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV PatientsCompletedNCT00703560
- A Study of MDX-1106 to Treat Patients With Hepatitis C InfectionCompletedNCT00703469Phase 1
- FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver TransplantationStatus unknownNCT00701272
- Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected SubjectsCompletedNCT00696904Phase 1
- Safety Study of SPC3649 in Healthy MenCompletedNCT00688012Phase 1
- NIDDM and IR in Combination Therapy for CHCCompletedNCT00687999Not applicable
- Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in NonrespondersCompletedNCT00684268Phase 2
- Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C TherapyWithdrawnNCT00682591
- Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral TreatmentCompletedNCT00680342Phase 2
- Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 PatientsCompletedNCT00680173Phase 4
- Effect of Immunosuppression Drug Weaning on Hepatitis C Virus (HCV)-Induced Liver Damage After Liver TransplantationCompletedNCT00668369Phase 2
- A Single Ascending Dose Study of BMS-791325 in HCV Infected SubjectsCompletedNCT00664625Phase 1/2
- High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4TerminatedNCT00662220Phase 3
- Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)Status unknownNCT00662194
- Hepatitis C Treatment and AtherosclerosisCompletedNCT00659256
- Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission PracticesCompletedNCT00657397Phase 3
- A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3CompletedNCT00656006Phase 2
- Prevention of Depression in HIV/HCV Co-infected Substance Abuse PatientsTerminatedNCT00655226Not applicable
- Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554CompletedNCT00651027Phase 1
- Efficacy of an Exercise Intervention to Decrease Depressive Symptoms in Veterans With Hepatitis CCompletedNCT00643695Not applicable
- Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and RibavirinTerminatedNCT00641654Phase 4
- Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis CStatus unknownNCT00638144
- Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With VasopressinStatus unknownNCT00635310Not applicable
- Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis CWithdrawnNCT00633230Phase 1
- Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular CarcinomaCompletedNCT00630084Phase 4
- Genetic Polymorphisms of Interleukin-10 and TNF-α on Outcome of HCV-Related Chronic Liver DiseaseStatus unknownNCT00630006Not applicable
- A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 PatientsCompletedNCT00629967Phase 4
- Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis CCompletedNCT00629824Phase 4
- Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 NonrespondersCompletedNCT00624325Phase 2/3
- Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C InfectionCompletedNCT00623649Phase 1
- Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4CompletedNCT00612755Phase 4
- Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCVStatus unknownNCT00611819Phase 4
- Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver DiseaseCompletedNCT00610597
- FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral TherapyCompletedNCT00606528
- Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide VaccineCompletedNCT00602784Phase 2
- Virological Response Study of the HCV Vaccine IC41CompletedNCT00601770Phase 2
- Psychoeducation for Hepatitis and Alcohol BehaviorsCompletedNCT00598416Not applicable
- Chronic Hepatitis Intervention Project for Drug UsersCompletedNCT00596843Phase 3
- Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis CCompletedNCT00593151Phase 1/2
- Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase LevelsStatus unknownNCT00575627Phase 4
- Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9CompletedNCT00575224Phase 4
- Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive PatientsWithdrawnNCT00571714Not applicable
- Study of CTS-1027 in Hepatitis C PatientsCompletedNCT00570336Phase 2
- Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus InfectionCompletedNCT00565539Phase 1
- Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)CompletedNCT00564811Not applicable
- Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV PatientsStatus unknownNCT00563173Phase 1/2
- A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated CirrhosisCompletedNCT00562783Phase 2
- The Effect of Adding Metformin to the Treatment of Hepatitis CCompletedNCT00560690Phase 4
- A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.CompletedNCT00560274Phase 4
- A Single Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00559247Phase 1/2
- Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy AdultsCompletedNCT00557583Phase 1
- Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected PatientsCompletedNCT00553930Phase 4
- Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C InfectionWithdrawnNCT00547716Not applicable
- Treatment Insulin Resistence in HCV G-1 PatientCompletedNCT00546442Phase 4
- Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIVCompletedNCT00545558Phase 1
- Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in TaiwanStatus unknownNCT00543244
- Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis CCompletedNCT00540345Phase 4
- Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-respondersCompletedNCT00538811Phase 2/3
- Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVRCompletedNCT00532701Phase 4
- Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous TherapiesCompletedNCT00530972Phase 4
- Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C VirusCompletedNCT00529321Phase 1
- Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis PatientsCompletedNCT00527774
- Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis CCompletedNCT00527540Phase 3
- Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected PatientsStatus unknownNCT00526448Phase 4
- A Study of the PK, Safety and Antiviral Activity of A-831 in HCV CarriersTerminatedNCT00522808Phase 1/2
- Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior TreatmentCompletedNCT00519792Phase 1